Theriva Biologics (Theriva Biologics) Earnings per Share (Diluted)

: $-1.16 (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

Theriva Biologics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16.

Theriva Biologics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16.

Theriva Biologics's EPS without NRI for the three months ended in Dec. 2023 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16.

During the past 3 years, the average EPS without NRIGrowth Rate was 44.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 52.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 43.10% per year.

During the past 13 years, Theriva Biologics's highest 3-Year average EPS without NRI Growth Rate was 65.70% per year. The lowest was -68.10% per year. And the median was 39.70% per year.

Theriva Biologics Earnings per Share (Diluted) Historical Data

The historical data trend for Theriva Biologics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-9.80

-6.60

-1.90

-1.31

-1.14

Theriva Biologics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.44	-0.30	-0.34	-0.19	-0.33

Competitive Comparison

For the Biotechnology subindustry, Theriva Biologics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theriva Biologics PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Theriva Biologics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's PE Ratio falls into.

Theriva Biologics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Theriva Biologics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-18.349	-	0)	/	16.107
	=	-1.14

Theriva Biologics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-5.485	-	0)	/	17.074
	=	-0.32

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Theriva Biologics (AMEX:TOVX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Theriva Biologics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Theriva Biologics (Theriva Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

SFY:Germany

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Executives

Steven A Shallcross	director, officer: CEO and CFO	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro	officer: Chief Operating Officer	9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan	director
Scott Tarriff	director	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman	officer: CHIEF MEDICAL OFFICER	9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp	10 percent owner	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne	officer: CHIEF FINANCIAL OFFICER	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks	director	C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr	director, officer: CEO & President	C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome	officer: Chief Scientific Officer	3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman	director
Wayne George Holman	10 percent owner	430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022